ArticleAnnals of hematology2026
Balancing safety and efficacy of Bendamustine plus anti CD20 regimens in elderly patients (> 70 y) with follicular lymphoma: a tertiary academic center experience.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL) in Western countries, with 65 beign the average age at diagnosis [1]. First-line treatment regimens combining Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) have shown favorable outcomes in pivotal trials [2-4]. Their efficacy and safety in patients aged 70 or older, who often receive reduced doses, remain unclear. This retrospective study evaluated the impact of reduced Bendamustine Delivered Dose Intensity [DDI, calculated as the total amount of Bendamustine (mg/m²) administered divided by the time taken to complete the regimen, with imputation for missed cycles] on outcomes and toxicities in FL patients (grade 1-3a) aged 70 or older treated with B-R or B-G between January 2014 and December 2023 at our center. Patients were categorized in reduced intensity (Low-DDI) and full intensity (High-DDI), based on the median DDI of the cohort. Efficacy was evaluated in the low DDI vs. high DDI setting, while toxicity outcomes were evaluated in the elderly (age ≥ 70 < 75 years) vs. very elderly (age ≥ 75yrs) population. Primary outcomes included progression-free survival (PFS) and overall survival (OS). Secondary outcomes included response rates, Progression of disease at 24 months (POD24) and toxicities. Among 139 FL patients, 39 met inclusion criteria (median follow-up: 73 months). Median OS was 31.5 vs. 65.0 months (p 0.238) and median PFS was 20.5 vs. 28.0 months (p = 0.081) for low- (n = 20) and high-DDI (n = 19), respectively. ORR was 78.9% vs. 100% (p = 0.105); CRR was 36.8% vs. 72.2% (p = 0.067). POD24 rates were similar (29.4% vs. 22.2%, p = 0.711). Patients were significantly older in the low-DDI group; other baseline features were comparable. Toxicity analysis showed no significant difference in grade ≥ 3 hematologic (p = 0.399) or non-hematologic (p = 0.920) events, or rate of hospitalization (p = 0.378) between elderly and very elderly. Secondary primary malignancies (SPM) occurred in 13 patients (34.2%), with no difference between groups. These findings support the feasibility of bendamustine dose reduction in elderly FL patients, showing no significant compromise in efficacy or increased toxicity. However, larger prospective studies are needed to confirm optimal dosing strategies in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.